Moreover, inhibiting CCL5 significantly reduced TAM-induced PCSC self-renewal in vivo, highlighting CCL5 and STAT3 as promising therapeutic targets for suppressing PCa metastasis and treatment resistance [33,34]. The gene discussed is CCL5; the disease is posterior cortical atrophy.